Litigation

Denmark, Enforcement, Generics, Infringement, Injunction, Litigation, Patents, Pharma, Pharmaceutical patent, Utility model

(Bugge Valentin)/ /4 Comments

In an appeal of a PI decision, the Danish Eastern High Court has ruled to uphold the dismissal of Novartis’ application for a preliminary injunction against Glenmark, Zentiva, and Viatris, based on the European patent application 2 959 894. In its decision, the Court firmly stated that a preliminary injunction can only be issued based…

Case Law, Damages, Litigation, Patents, United Kingdom

(Bristows)/

Geofabrics Limited v Fiberweb Geosynthetics Limited [2022] EWHC 2363 (Pat) Geofabrics Limited (“Geofabrics”) has been awarded £13.4 million in damages for patent infringement, concluding a 5 year long dispute with Fiberweb Geosynthetics Limited (“Fiberweb”).  Damages inquiries are rare in the UK so this judgment from Charlotte May KC (sitting as a Deputy High Court Judge),…

(Cross-border) jurisdiction, Covid-19, France, Litigation, Patents, Pharmaceutical patent

(Dhenne Avocats)/ /7 Comments

The news was announced last week: Moderna is suing Pfizer for infringement of two of its patents related to Covid-19 vaccines. These highly targeted actions are likely to spread to many other countries: here is a brief overview of the case and its potential French perspective. In a press release dated August 26, 2022, Moderna…

Amendments, Case Law, Competition, Generics, Kluwer Patent Cases, Litigation, Patents, Pharma, Pharmaceutical patent, Procedure, Revocation, United Kingdom, Validity

(Bristows)/

On 15 to 17 December 2021 a three-day trial took place to determine preliminary issues in a second action brought by Neurim against Mylan in relation to patents protecting the product Circadin (“Neurim v Mylan 2021”).  Meade J’s judgment (Neurim Pharmaceutical (1991) Limited and Anor v Generics (UK) Limited t/a Viatris and Anor [2022] EWHC…

(Cross-border) jurisdiction, FRAND, Injunction, Litigation, Netherlands, Patents, Procedure, SEP

(Brinkhof)/

In two recent decisions the District Court of The Hague assumed cross-border jurisdiction in FRAND / Standard Essential Patent (‘SEP’) proceedings. In a first case the Court assumed jurisdiction on claims related to the FRANDness of a SEPs (patent pool) license. In a second case the Court assumed jurisdiction on an anti-anti-suit injunction (‘AASI’) claim…

Denmark, Litigation, Patents

(Bugge Valentin)/

On September 30th, 2021, the Danish High Court (Eastern Division) rendered its decision in a long running patent infringement case. One important element of the case was the question of acquiescence, in particular, whether the patent pro-prietor is required to act on a possible patent infringement (and commence legal proceedings) when opposition proceedings are pending….

(Cross-border) jurisdiction, (Indirect) infringement, China, Competition, Enforcement, FRAND, Germany, Infringement, Injunction, Litigation, Patents, SEP, United Kingdom, United States of America

(Bristows)/ /1 Comment

This short post reports on one of the Panel Sessions at this year’s AIPPI Congress which took place virtually for the second year in a row. The tenth panel session of the AIPPI Online World Congress 2021 addressed global FRAND determinations by national courts and out-of-jurisdiction judgments in the form of anti-suit and anti-anti-suit injunctions….

Litigation, Patents, Procedure, Switzerland

(MLL Legal Ltd.) and (Meyerlustenberger Lachenal Ltd. (MLL))/ /5 Comments

In a recent decision, the Swiss Federal Supreme Court – Switzerland’s highest court also in patent matters – dealt with the question of whether the assessment of patent claims is fundamentally a question of law or a question of fact. This distinction is relevant under Swiss law for example because in Switzerland, after the conclusion…

Damages, European Union, France, IP Management, Litigation, Patents, Procedure

(Dhenne Avocats)/ /7 Comments

My eminent colleague Pierre Véron, who needs no introduction here, is the author of a recent survey on the ranking of European jurisdictions in terms of damages awarded over the period 2000-2019 [1]The full version was published in English in Festschrift for President Meier-Beck in the journal GRUR (GRUR 2/2021)., which particularly caught my attention…

Litigation, Pharmaceutical patent, Plausibility, Second Medical Use, Sufficiency of disclosure, United Kingdom, Validity

, (Bristows)/ /1 Comment

In undoubtedly one of the most important decisions of the year so far, on 24 August 2021, the English Court of Appeal handed down its judgment in FibroGen v Akebia (FibroGen Inc v Akebia Therapeutics Inc [2021] EWCA Civ 1279), partially allowing FibroGen’s appeal, and so finding one of the ‘Family A’ patents, EP 823,…